2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
195
Neoplasm Metastasis
22
Prostatic Neoplasms, Castration-Resistant
20
Breast Neoplasms
19
Neoplasms
18
Metastatic Castration Resistant Prostate Cancer
10
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Triple Negative Breast Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Castration-resistant Prostate Cancer
5
Carcinoma, Non-Small-Cell Lung
5
Melanoma
4
Carcinoma, Hepatocellular
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Prostate Adenocarcinoma
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
mCRPC
2
Uterine Cervical Neoplasms
2
Recurrence
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Interventions
Cisplatin
7
Etoposide
6
pembrolizumab
4
Topotecan
4
Pemetrexed
4
Carboplatin
4
Gemcitabine
3
belinostat
2
Temozolomide
2
RRx-001
2
Paclitaxel
2
vosaroxin
1
vinflunine
1
veliparib
1
taxane
1
sagopilone
1
sacituzumab govitecan
1
pomalidomide
1
lurtotecan
1
liposomal doxorubicin
1
etoposide phosphate
1
enzalutamide
1
bemiparin
1
belotecan
1
atezolizumab
1
apalutamide
1
alvocidib
1
abiraterone
1
Vinorelbine
1
Tomography, X-Ray Computed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Small Cell
×
enzalutamide
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts